PFC
ITCI icon

Phocas Financial Corp’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Phocas Financial Corp’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,058
Closed -$1.59M – 165
2024
Q4 		$1.59M Buy
+19,058
New +$1.57M 0.21% 117
2023
Q4 		$1.95M Buy
+27,210
New +$1.57M 0.26% 116

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HBK Investments
HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Davidson Kempner Capital Management
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UBS O'Connor
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Phocas Financial Corp's ITCI Position: Q1 2025 in Review

Phocas Financial Corp sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 19,058 shares — an estimated $1.59M sold.

Phocas Financial Corp first reported a position in ITCI in Q4 2023 and held it in 2 quarters. The position peaked at $1.95M in Q4 2023. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Phocas Financial Corp reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Phocas Financial Corp sold 19,058 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $1.59M.
  • Phocas Financial Corp first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 2 quarters.
  • Phocas Financial Corp's Intra-Cellular Therapies Inc. position peaked at $1.95M in Q4 2023.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Phocas Financial Corp's 13F filing for Q1 2025, filed 9 May 2025.